The Merck Accelerator Program 2019

MerckThe Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites events in Africa, startups can find their perfect fit and connect to the global network for collaboration. Are you ready to partner with Merck?

Applications for the HQ Program are open! From July until the end of September Merck will be looking for startups to join the Accelerator Program in Darmstadt. Come to the headquarters to connect with worldwide decision-makers and win Merck as your business partner. Take your chance to extend your stay in the Innovation Hub in China and succeed in accessing the Chinese market.

What are the key benefits of Merck Accelerator?

  • Partnership: Merck Accelerator is looking for strong business alliances and want to partner up with promising startups to build sustainable and successful business relationships.
  • Mentoring: Receive mentoring from members of Senior Management and Merck global network of over 50,000 experts. Dive deep into mentoring sessions and workshops.
  • Curriculum: Benefit from tailored coaching sessions and workshops provided by the Innovator Academy.
  • Funding: Kick off your startup project with seed funding of up to €50,000 and access Merck Accelerator investor network.
  • Access to the Chinese Market: Selected startups will also have the chance to extend their stay by joining our China Innovation Hub
  • Community: Team up with others facing the same challenges and build lifelong relationships.

A bustling city in the heart of Germany

The Rhine-Main region is a culturally and economically vibrant region in Hesse, Germany. It is home to the metropolises of Frankfurt and the state capitals of Wiesbaden and Mainz. Darmstadt is a city well-accustomed to witnessing big developments in science and high-tech. The city is home to several renowned scientific and technological institutions, as well as many great discoveries in chemistry and physics. Darmstadt has also been named "Digital City" and "City of the Future" in recognition of its status as Germany's most promising digital location of the future.

Are you ready to access the Chinese market?

Following the HQ program, selected startups could qualify to participate in the Merck Accelerator extension in China. They will get guidance to access the Chinese Market, as well as insights on the local regulatory affairs and customers-base. The HQ Accelerator Program is therefore complemented by a tailored Program in the China Innovation hub in Shanghai in which the startups will be able to choose curriculum and mentoring subjects, as well as trainings for localizing their business model in China and developing partnership strategies.

Start your journey in the Merck headquarter in Darmstadt, Germany and use your chance to also get access to the Chinese market via Merck.

When & Where

The HQ Accelerator program application phase is running from July until September 2018.
The HQ Accelerator intake will take place from January until April 2019 (3 months at the Innovation Center).

Are you a startup operating in the fields of healthcare, performance materials, life sciences, and other related business fields?

Then apply now via the web link below:
https://www.f6s.com/acceleratorprogram2019

Application submission deadline: September 30th 2018

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...